Abiopharma

Assertio Holdings, Inc. - Assertio Reports Second Quarter 2025 Financial Results

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

New Form 8-K - Ecovyst Inc. Filed: 2025-08-11 AccNo: 0001193125-25-177926 Size: 138 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

New Form 8-K - ReShape Lifesciences Inc. Filed: 2025-08-11 AccNo: 0001104659-25-076151 Size: 195 KB Item 5.07: Submission of Matters to a Vote of Security Holders

New Form 144 - Warby Parker Inc. Filed: 2025-08-11 AccNo: 0001950047-25-005597 Size: 4 KB

BioVie Inc. - BioVie Inc. Announces Closing of $12 Million Public Offering

New Form 8-K - FIBROGEN INC Filed: 2025-08-11 AccNo: 0000950170-25-106534 Size: 467 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form DEFA14A - XWELL, Inc. Filed: 2025-08-11 AccNo: 0001104659-25-076152 Size: 70 KB

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New Form 4 - Cyclerion Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0000950170-25-106532 Size: 5 KB

New Form 4 - AGENUS INC Filed: 2025-08-11 AccNo: 0000950170-25-106531 Size: 7 KB

New Form 144 - Vor Biopharma Inc. Filed: 2025-08-11 AccNo: 0001950047-25-005593 Size: 17 KB

New Form 144 - iRhythm Technologies, Inc. Filed: 2025-08-11 AccNo: 0001950047-25-005591 Size: 5 KB

New Form 8-K - Xenon Pharmaceuticals Inc. Filed: 2025-08-11 AccNo: 0000950170-25-106529 Size: 439 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits